Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, 2026, highlighting a 196% year-over-year increase in Nociscan scan volumes and a 64% sequential increase from Q4 2025. The company attributes the growth to new account activations and deeper utilization within existing sites, signaling that its Nociscan platform is becoming more integrated into clinical workflows for chronic low back pain management.
Nociscan uses magnetic resonance spectroscopy data and proprietary augmented intelligence algorithms to help physicians identify painful discs. The company noted that approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for Nociscan. Repeat usage trends reinforce the platform's value proposition, positioning Aclarion for sustained expansion.
On the reimbursement front, Nociscan has secured coverage from three of the four largest private insurers in the U.K.—Vitality, AXA, and Aviva—providing early payer validation. Aclarion also launched a targeted direct-to-patient campaign in the U.K., featuring a video with Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. The company continues to engage U.S. payers through its Nociscan Reimbursement Program.
Clinical development is advancing with the CLARITY randomized trial, designed to validate Nociscan's clinical utility in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions.
Aclarion strengthened its intellectual property portfolio with a newly issued patent covering the use of AI in workflows of future products, bringing its total to 64 issued and pending patents worldwide. The company believes this enhances its competitive moat and supports scaling while maintaining strong gross margins.
Financially, Aclarion ended Q1 2026 with $19.0 million in cash and no debt. With 2,444,871 common shares outstanding as of March 31, 2026, and 2,882,371 on a fully diluted basis, the company has approximately $6.60 per share in cash. A $2.5 million share repurchase program announced this week, combined with current cash resources, is expected to fund operations into the second half of 2027.
“Q1 represents a clear inflection for Aclarion,” said Brent Ness, CEO of Aclarion. “Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.”
The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom. For more information on Nociscan, visit www.aclarion.com.
